Obesity and Cardiovascular Disease: Pathogenic Mechanisms and Potential Benefits of Weight Reduction

ABSTRACT

The prevalence of obesity in industrialized countries has reached epidemic proportions, with about one in three people being obese and another one in three people being overweight and at risk of developing obesity. In recent years, obesity has gained the traditional tetrad of cardiovascular risk factors of smoking: hypertension, dyslipidemia, and dysglycemia. Attention has also focused on the importance of abdominal (or central) obesity as a determinant of cardiovascular risk, independent of the body mass index. In addition to effects on coronary artery disease, obesity has an effect on cardiovascular disease, including stroke, ventricular function, peripheral arterial disease, and venous thromboembolism. The objectives of this review are to summarize the effects of obesity on cardiovascular disease, and the possible mechanisms for these associations, and to investigate the effects of weight-loss interventions on the burden of cardiovascular disease. Large ongoing clinical outcome trials, such as the SOS study, the Look-AHEAD trial, or the SCOUT study, should provide important information on the effects of surgical and nonsurgical obesity treatment on cardiovascular morbidity and mortality.

KEYWORDS

Obesity - pathogenesis - weight loss - cardiovascular disease

REFERENCES

• 1 Assmann G, Carmena R, Cullen P et al.. Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease.  Circulation. 1999;  100 1930-1938
• 2 World Health Organization Consultation on Obesity .Obesity: preventing and managing the global epidemic. Geneva; World Health Organization 2000
• 3 Rabkin S W, Chen Y, Leiter L, Liu L, Reeder B A. Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group.  CMAJ. 1997;  157 Suppl 1 S26-S31
• 4 Eckel R H, Krauss R M. for the AHA Nutrition Committee, American Heart Association: call to action: obesity as a major risk factor for coronary heart disease.  Circulation. 1998;  97 2099-2100
• 5 Han T S, van Leer E M, Seidell J C, Lean M E. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample.  BMJ. 1995;  311 1401-1405
• 6 Donohue R P, Abbott R D, Bloom E, Reed D M, Yano K. Central obesity and coronary heart disease in men.  Lancet. 1987;  1 821-824
• 7 Lean M E, Han T S, Seidell J C. Impairment of health and quality of life in people with large waist circumference.  Lancet. 1998;  351 853-856
• 8 Lemieux I, Pascot A, Couillard C et al.. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?.  Circulation. 2000;  102(2) 179-184
• 9 Despres J P. Health consequences of visceral obesity.  Ann Med. 2001;  33 534-541
• 10 Mokdad A H, Serdula M K, Dietz W H, Bowman B A, Marks J S, Koplan J P. The spread of the obesity epidemic in the United States, 1991-1998.  JAMA. 1999;  282 1519-1522
• 11 Katzmarzyk P T. The Canadian obesity epidemic, 1985-1998.  CMAJ. 2002;  166 1039-1040
• 12 Seidell J C. The epidemiology of obesity. in Björntorp P International Textbook of Obesity Chichester; Wiley 2001: 23-29
• 13 Martorell R, Kettel-Khan L, Hughes M L, Grummer-Strawn L M. Obesity in women from developing countries.  Eur J Clin Nutr. 2000;  54 247-252
• 14 Flegal K M, Carroll M D, Ogden C L, Johnson C L. Prevalence and trends in obesity among US adults, 1999-2000.  JAMA. 2002;  288 1723-1727
• 15 King H, Aubert R E, Herman W H. Global burden of diabetes, 1995-2025.  Diabetes Care. 1998;  21 1414-1431
• 16 Keys A, Menotti A, Aravanis C et al.. The seven countries study: 2289 deaths in 15 years.  Prev Med. 1984;  13 141-154
• 17 Rimm E B, Stampfer M J, Giovannucci E et al.. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men.  Am J Epidemiol. 1995;  141(12) 1117-1127
• 18 Manson J E, Colditz G A, Stampfer M J et al.. A prospective study of obesity and risk of coronary heart disease in women.  N Engl J Med. 1990;  322 882-889
• 19 Rosengren A, Wedel H, Wilhelmsen L et al.. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study.  Eur Heart J. 1999;  20(4) 269-277
• 20 Manson J E, Willet W C, Stampfer M J et al.. Body weight and mortality among women.  N Engl J Med. 1995;  333 677-685
• 21 Stevens J, Cai J, Pamuk E R, Williamson D F, Thun M J, Wood J L. The effect of age on the association between body mass index and mortality.  N Engl J Med. 1998;  338 1-7
• 22 Engeli S, Sharma A M. Role of adipose tissue for cardiovascular-renal regulation in health and disease.  Horm Metab Res. 2000;  32 485-499
• 23 Haynes W G. Interaction between leptin and sympathetic nervous system in hypertension.  Curr Hypertens Rep. 2000;  2 311-318
• 24 Parhami P, Tintut Y, Ballard A, Fogelman A M, Demer L L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin.  Circ Res. 2001;  88 954-960
• 25 Narklewicz K, Kato M, Phillips B G et al.. Leptin interacts with heart rate but not sympathetic nerve traffic in healthy male subjects.  J Hypertens. 2001;  19 1089-1094
• 26 Engeli S, Negrel R, Sharma A M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system.  Hypertension. 2000;  35 1270-1277
• 27 Ouchi N, Kihara S, Arita Y et al.. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin.  Circulation. 1999;  100 2473-2476
• 28 Lohn M, Dubrovska G, Lauterbach B, Luft F C, Gollasch M, Sharma A M. Periadvential fat releases a vascular relaxing factor.  FASEB J. 2002;  16 1057-1063
• 29 Heilbronn L K, Noakes M, Clifton P M. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women.  Arterioscler Thromb Vasc Biol. 2001;  21 968-970
• 30 Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women.  Int J Obes Relat Metab Disord. 2001;  25 212-218
• 31 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med. 1997;  336 973-979
• 32 Lundgren C H, Brown S L, Nordt T K, Sobel B E, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential link between obesity and cardiovascular disease.  Circulation. 1996;  93 106-110
• 33 Abott R D, Behrens G R, Sharp D S et al.. Body mass index and thromboembolic stroke in nonsmoking men in older middle age: the Honolulu Heart Program.  Stroke. 1994;  25 2370-2376
• 34 Hubert H B, Feinleib M, McNamara P M, Castelli W P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.  Circulation. 1983;  67 968-977
• 35 Rexrode K M, Hennekens C H, Willett W C et al.. A prospective study of body mass index, weight change, and risk of stroke in women.  JAMA. 1997;  227 1539-1545
• 36 Suk S-H, Sacco R L, Boden-Albala B et al.. Abdominal obesity and risk of ischemic stroke. The Northern Manhattan Stroke Study.  Stroke. 2003;  34 1586-1592
• 37 Sacco R L, Boden-Albala B, Abel G et al.. Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan Stroke Study.  Stroke. 2001;  32 1725-1731
• 38 Arcaro G, Zamboni M, Rossi L et al.. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity.  Int J Obes Relat Metab Disord. 1999;  23 936-942
• 39 Solorte S B, Fiorvanti M, Pezza N et al.. Hyperviscosity and microproteinuria in central obesity: relevance to cardiovascular risk.  Int J Obes Relat Metab Disord. 1997;  21 417-423
• 40 Davi G, Guagnano M T, Ciabattoni G et al.. Platelet activation in obese women: role of inflammation and oxidant stress.  JAMA. 2002;  288 2008-2014
• 41 Alpert M A, Terry B E, Mulekar M et al.. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss.  Am J Cardiol. 1997;  80 736-740
• 42 Must A, Spadano J, Coakley E H, Field A E, Colditz G, Dietz W H. The disease burden associated with overweight and obesity.  JAMA. 1999;  282 1523-1529
• 43 Kuch B, Muscholl M, Luchner A et al.. Gender specific differences in left ventricular adaptation to obesity and hypertension.  J Hum Hypertens. 1998;  12 685-691
• 44 Dagenais G R, Maurice S, Robitaille N M, Gingras S, Lupien P J. Intermittent claudication in Quebec men from 1974-1986: the Quebec Cardiovascular Study.  Clin Invest Med. 1991;  14 93-100
• 45 Bainton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell prospective heart study.  Br Heart J. 1994;  72 128-132
• 46 Smith G D, Shipley M J, Rose G. Intermittent claudication, heart disease risk factors and mortality: The Whitehall Study.  Circulation. 1990;  82 1925-1931
• 47 Newman A B, Sutton-Tyrrell K, Vogt M T, Kuller L H. Morbidity and mortality in hypertensive adults with a low ankle/arm blood pressure index.  JAMA. 1993;  270 487-489
• 48 Planas A, Clara A, Pou J-M et al.. Relationship of obesity distribution and peripheral arterial occlusive disease in elderly men.  Int J Obes Relat Metab Disord. 2001;  25 1068-1070
• 49 Tsai A W, Chushman M, Rosamond W D et al.. Cardiovascular risk factors and venous thromboembolism incidence.  Arch Intern Med. 2002;  162 1182-1189
• 50 Hansson P-O, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity. Risk factors for venous thromboembolism among middle-aged men: “The Study of Men Born in 1913.”  Arch Intern Med. 1999;  159 1886-1890
• 51 Abdollahi M, Cushman M, Rosendaal F R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use.  Thromb Haemost. 2003;  89 493-498
• 52 Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study.  Arch Intern Med. 2000;  160 3415-3420
• 53 White H R, Gettner S, Newman J, Trauner K B, Romano S P. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty.  N Engl J Med. 2000;  343 1758-1764
• 54 Padberg F, Cerveira J J, Lal B K, Pappas P J, Varma S, Hobson R W. Does severe venous insufficiency have a different etiology in the morbidly obese? It is venous?.  J Vasc Surg. 2003;  37 79-85
• 55 Vague P, Juhan-Vague I, Aillaud M F et al.. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects.  Metabolism. 1986;  35 250-253
• 56 Quattrone A, Gambardella A, Carbone A M et al.. A hypofibrinolytic state in overweight patients with cerebral venous thrombosis and isolated intracranial hypertension.  J Neurol. 1999;  246 1086-1089
• 57 Foster G D, Wadden T A, Phelan S, Sarwer D B. Obese patients’ perceptions of treatment outcomes and the factors that influence them.  Arch Intern Med. 2001;  161 2133-2139
• 58 Oster G, Thompson D, Edelsberg J, Bird A P, Colditz G A. Lifetime effect and economic benefits of weight loss among obese persons.  Am J Public Health. 1999;  89 1536-1542
• 59 Blackburn G. Effect of degree of weight loss on health benefits.  Obes Res. 1995;  (suppl 2) 211S-216S
• 60 Goldstein D J. Beneficial effects of modest weight loss.  Int J Obes Relat Metab Disord. 1992;  16 397-415
• 61 Balsiger B M, Murr M M, Poggio J L, Sarr M G. Bariatric surgery. Surgery for weight control in patients with morbid obesity.  Med Clin North Am. 2000;  84 477-489
• 62 Guerciolini R. Mode of action of orlistat.  Int J Obes Relat Metab Disord. 1997;  21 (suppl) 3 S12-S52
• 63 Finer N. Sibutramine: its mode of action and efficacy.  Int J Obes Relat Metab Disord. 2002;  26(suppl 4) S29-S33
• 64 Douketis J D, Feightner J W, Attia J, Feldman W F. Periodic health examination, 1999 update: detection, prevention, and treatment of obesity. Canadian Task Force on Preventive Health Care.  CMAJ. 1999;  160 513-524
• 65 Douketis J D, Thabane L, Macie C, Williamson D F. The long-term effectiveness of weight reduction in obese and overweight adults: systematic review and generalizability of findings to clinical practice.  Int J Obes Relat Metabol Disord. 2005;  , In press
• 66 Tuomilehto J, Lindström J, Eriksson J G et al.. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 67 Eriksson K F, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise.  Diabetologia. 1991;  34 891-898
• 68 The Trials of Hypertension Prevention Collaborative Research Group . Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II.  Arch Intern Med. 1997;  157 657-667
• 69 Stevens V J, Obarzanek E, Cook N R et al.. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, Phase II.  Ann Intern Med. 2001;  134 1-11
• 70 Whelton P K, Appel L J, Espeland M A et al.. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group.  JAMA. 1998;  279 839-846
• 71 Stamler R, Stamler J, Grimm R et al.. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial-The Hypertension Control Program.  JAMA. 1987;  257 1484-1491
• 72 Metz J A, Stern J S, Kris-Etherton P et al.. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction.  Arch Intern Med. 2000;  160 2150-2158
• 73 Pischon T, Douketis J D, Sharma A M. Evidence based medicine: weight loss and cardiovascular risk factor. In: Hofbaver KG, Keller U, Boss O Pharmacotherapy of Obesity Boca Raton, FL; CRC Press 2004: 155-172
• 74 Hollander P A, Elbein S C, Hirsch I B et al.. Role of orlistat in the treatment of obese patients with type 2 diabetes.  Diabetes Care. 1998;  21 1288-1294
• 75 Lindgärde F. on behalf of the Orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study.  J Intern Med. 2000;  248 245-254
• 76 Kelley D E, Bray G A, Pi-Sunyer F X et al.. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes.  Diabetes Care. 2002;  25 1033-1041
• 77 Miles J M, Leiter L, Hollander P et al.. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.  Diabetes Care. 2002;  25 1123-1128
• 78 Sharma A M, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension.  J Hypertens. 2002;  20 1873-1878
• 79 McMahon F G, Fujioka K, Singh B N et al.. Efficacy and safety of sibutramine in obese white and African American patients with hypertension. A 1-year, double-blind, placebo-controlled, multicenter trial.  Arch Intern Med. 2000;  160 2185-2191
• 80 McMahon F G, Weinstein S P, Rowe E, Ernst K R, Johnson F, Fujioka K. and the Sibutramine in Hypertension Clinical Study Group . Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.  J Hum Hypertens. 2002;  16 5-11
• 81 Expert Panel on the Identification . Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults.  Arch Intern Med. 1998;  158 1855-1867
• 82 Ornish D, Brown S E, Scherwitz L W et al.. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial.  Lancet. 1990;  336 129-133
• 83 Haskell W L, Alderman E L, Fair J M et al.. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease.  Circulation. 1994;  89 975-990
• 84 Niebauer J, Hambrecht R, Velich T et al.. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention.  Circulation. 1997;  96 2534-2541
• 85 Schuler G, Hambrecht R, Schlierf G et al.. Regular physical exercise and low-fat diet.  Circulation. 1992;  86 1-11
• 86 Blood Pressure Lowering Trialists’ Collaboration . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.  Lancet. 2000;  355 1955-1964
• 87 Anonymous . Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of cardiovascular complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.  Lancet. 1998;  352 837-853
• 88 Torgerson J S, Sjostrom L. The Swedish Obese Subjects (SOS) study - rationale and results.  Int J Obes Relat Metab Disord. 2001;  25 (suppl) 1 S2-S4
• 89 Ryan D H, Espeland M A, Foster G D et al.. Look AHEAD (Action for Health in Diabetes): design and method for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.  Control Clin Trials. 2003;  24(5) 610-628
• 90 Decline in deaths from heart disease and stroke - United States, 1900-1999.  MMWR Morb Mortal Wkly Rep. 1999;  48 649-656